FMP

FMP

Enter

ADMA - ADMA Biologics, Inc.

Financial Summary of ADMA Biologics, Inc.(ADMA), ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketi

photo-url-https://financialmodelingprep.com/image-stock/ADMA.png

ADMA Biologics, Inc.

ADMA

NASDAQ

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

6.37 USD

-0.09 (-1.41%)

About

ceo

Mr. Adam S. Grossman

sector

Healthcare

industry

Biotechnology

website

https://www.admabiologics.com

exchange

NASDAQ

Description

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and pre...

CIK

0001368514

ISIN

US0008991046

CUSIP

000899104

Address

465 State Route 17

Phone

201 478 5552

Country

US

Employee

624

IPO Date

Oct 17, 2013

Summary

CIK

0001368514

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

000899104

ISIN

US0008991046

Country

US

Price

6.37

Beta

0.43

Volume Avg.

2.53M

Market Cap

1.48B

Shares

-

52-Week

3.06-6.76

DCF

-0.04

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-49

P/B

-

Website

https://www.admabiologics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ADMA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep